Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon

• Verfasst von: Furlanetto, Jenny [VerfasserIn]
• Verfasst von: Marmé, Frederik [VerfasserIn]
• Verfasst von: Loibl, Sibylle [VerfasserIn]
• Titel: Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon
• Titelzusatz: drug evaluation
• Verf.angabe: Jenny Furlanetto, Frederik Marmé and Sibylle Loibl
• E-Jahr: 2022
• Jahr: 7 Sep 2022
• Umfang: 17 S.
• Fussnoten: Gesehen am 19.09.2023
• Titel Quelle: Enthalten in: Future oncology
• Ort Quelle: London : Taylor & Francis, 2005
• Jahr Quelle: 2022
• Band/Heft Quelle: 18(2022), 28, Seite 3199-3215
• ISSN Quelle: 1744-8301
• DOI: doi:10.2217/fon-2022-0407
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: antibody-drug conjugate
• Sach-SW: early breast cancer
• Sach-SW: metastatic breast cancer
• Sach-SW: sacituzumab govitecan
• K10plus-PPN: 1859927734

Abstract

Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor cells (bystander effect). SG showed efficacy and safety in several epithelial tumors. The phase III ASCENT trial led to the approval of SG (10 mg/kg, d1,8 q3w) in patients with advanced or metastatic triple-negative breast cancer (TNBC) who have received ≥2 prior systemic therapies, including ≥1 for metastatic disease. The phase III TROPiCS-02 trial in heavily pretreated advanced hormone receptor (HR)-positive breast cancer has recently shown an improvement in progression-free survival for patients treated with SG compared to single-agent chemotherapy. The phase III post-neoadjuvant SASCIA study in early high-risk TNBC and HR-positive breast cancer is currently recruiting patients.